Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus
| Autor: | Michiaki Fukui, Muhei Tanaka, Goji Hasegawa, Hidetaka Ushigome, Shinobu Matsumoto, Isao Yokota, Chikako Oyabu, Masahiro Yamazaki, Naoto Nakamura, Emi Ushigome |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Dihydropyridines Trichlormethiazide medicine.medical_specialty Azelnidipine Urology Tetrazoles Blood Pressure Pilot Projects 030204 cardiovascular system & hematology Type ii diabetes 03 medical and health sciences 0302 clinical medicine Combined treatment Internal medicine Internal Medicine medicine Humans In patient 030212 general & internal medicine Diuretics Antihypertensive Agents Aged Morning Cross-Over Studies business.industry Imidazoles Blood Pressure Monitoring Ambulatory Middle Aged Calcium Channel Blockers Blood pressure Endocrinology Diabetes Mellitus Type 2 Hypertension Drug Therapy Combination Female Cardiology and Cardiovascular Medicine Olmesartan business Angiotensin II Type 1 Receptor Blockers Azetidinecarboxylic Acid medicine.drug |
| Zdroj: | Journal of the American Society of Hypertension. 11:140-147 |
| ISSN: | 1933-1711 |
| DOI: | 10.1016/j.jash.2016.12.004 |
| Popis: | The aim of the present study was to compare the effects of olmesartan combined with azelnidipine versus olmesartan combined with trichlormethiazide, on home blood pressure (BP) and pressure variability in type II diabetes mellitus patients using home BP telemonitoring system. We performed an open-label cross-over pilot study of 28 patients with type II diabetes mellitus. Patients received combination treatment with either olmesartan 20 mg plus azelnidipine 16 mg or olmesartan 20 mg plus trichlormethiazide 1 mg for more than 6 weeks each in a cross-over method. The coefficient of morning systolic BP variability in the olmesartan plus azelnidipine group was significantly lower than that in the olmesartan plus trichlormethiazide group (6.4 ± 1.9 vs. 7.5 ± 2.6, P = .004). There were no significant differences in mean morning systolic BP between the two groups. Using home BP telemonitoring for hypertensive patients with type II diabetes, this study revealed for the first time that the olmesartan with azelnidipine combination is superior to the olmesartan with trichlormethiazide combination in reducing home BP variability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|